Hualan Bio, a leader in the Chinese biotechnology sector, and Pharmasyntez, a Russian pharmaceutical company, signed a memorandum on strategic cooperation within the framework of Bioprom 2025. In the area of cutting-edge medical technologies, this represented a significant advancement in the scientific and technological exchange between China and Russia.
Within the framework of the partnership, the parties will share important technologies and work together to create new high-tech biopharmaceuticals in the domains of industrial biotechnology and pharmaceuticals.
Hualan Bio is one of the largest and most powerful biotechnology companies in China. Hualan Biological Engineering Inc. was founded in 1992 as a national high-tech company, marking the beginning of the company's history. Over the course of its business, the company has focused on developing, producing, and commercializing blood plasma products, vaccines, and medications based on recombinant proteins. With cutting-edge production facilities and a wealth of genetic engineering and biotechnology expertise, Hualan Bio currently occupies a prominent position in the production of vaccines, monoclonal antibodies, and other biopharmaceuticals.
The primary areas of cooperation include technology transfer, in which Hualan Bio will grant access to its cutting-edge biopharmaceutical development platforms, allowing for the collaborative development of novel, potent medications. Specialists from both companies will pool their expertise to carry out cooperative R&D projects, especially in the area of creating ground-breaking therapeutic monoclonal antibodies. Production localization is given a lot of attention: Pharmasyntez Group's state-of-the-art production facilities in Russia will produce some of the biopharmaceuticals using a full-cycle process. This will help satisfy the strategic demands of the domestic market and promote import substitution.
Additionally, the parties intend to work together to expand the reach of cutting-edge biotechnological solutions by registering and commercializing the developed drugs both inside and outside of the Eurasian Economic Union.
The partnership between Hualan Genetics and Pharmasyntez, a Russian company, in the areas of technology transfer and antibody production is extremely important. First, it will shorten the time from Pharmasyntez's development to clinical application and expedite the integration of Hualan Genetics' biotechnological innovations into industrial manufacturing. Second, by working together, the partners will be able to take their complementary advantages: Pharmasyntez provides its vast clinical experience and market resources, while Hualan Bio contributes its state-of-the-art manufacturing and scientific advancements, promoting mutually beneficial progress. Furthermore, collaborative efforts will strengthen the strategic security of pharmaceuticals in both countries and advance the development of biopharmaceutical innovations. This strategy will improve public health and significantly advance global healthcare,
An Wenqi, Director of Hualan Biological Engineering stated.
Biopharmaceuticals is a complex and dynamically developing field that is becoming the foundation of the future of medicine. Rapid advancement and creative breakthroughs are impossible without international collaboration and resource pooling. In this regard, we have an agreement with Hualan, one of China's top biopharmaceutical companies, regarding cooperative efforts in technology transfer, the development of new drugs, market expansion in China and Russia, and the export of completed solutions to developing countries. Such a strategic partnership will open new horizons for Russian innovations and make our country more competitive in the global biotechnology market,
the President of the Pharmasyntez Group stated.